How a gut oxygen sensor boosts natural GLP-1 and controls blood sugar
Official title: Role of Hypoxia-inducible factor-2a in L-cell nutrient sensing and metabolic homeostasis
Funded at University of Pittsburgh at Pittsburgh · NIH-11333263 · Data updated 2026-11-12
Looks at whether an oxygen-sensing protein in the gut helps meals trigger GLP-1 release to improve blood sugar control for people with type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | July 1, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $459,942 |
| NIH project number | 5R01DK133406-05 |
| Project ID | NIH-11333263 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with type 2 diabetes who want better blood sugar control or alternatives to existing GLP-1–based therapies would be the most relevant patients for future clinical work from this project.
✕Less likely to help
People without type 2 diabetes or those whose diabetes is already well controlled and not seeking GLP-1–based options are unlikely to receive direct benefit from this work.
What this research studies
Researchers will use mouse models, intestinal cell experiments, and molecular analyses to learn how HIF-2α in gut L-cells responds to nutrients and controls GLP-1 secretion. They will study how HIF-2α changes expression of the lipid sensor GPR40 and how the metabolite α-ketoglutarate contributes to nutrient signaling. Experiments include genetic disruption and short-term inhibition of HIF-2α, tests of lipid-stimulated GLP-1 release, and glucose tolerance measurements in animals. The aim is to identify mechanisms that could be targeted to boost the body’s own GLP-1 without the gastrointestinal side effects seen with some current GLP-1 drugs.
Why it matters
Potential benefit: Could point to new treatments that increase your own GLP-1 release to lower blood sugar while causing fewer intestinal side effects than current GLP-1 drugs.
How similar studies have gone: GLP-1–based drugs reliably lower blood sugar but often cause GI side effects, and targeting L-cell secretion through HIF-2α is a novel approach with promising preclinical (mouse) data but not yet tested in humans.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Ramakrishnan, Sadeesh Kumar — University of Pittsburgh at Pittsburgh
- Study coordinator: Ramakrishnan, Sadeesh Kumar
Related research
Other NIH-funded projects on the same topics.
-
Using MRI to measure brain oxygen levels as an early sign of small vessel disease in the brain
This study is looking at how measuring oxygen levels in the brain with MRI can help spot early signs of small vessel disease, which is linked to memory problems and dementia, especially Alzheimer's, so if you're at risk due to age or high blood pressure, you might be able to participate in MRI scans to learn more about
-
HIF-driven ways to repair damaged lungs in IPF
A doctor-researcher is testing how low-oxygen signals (HIF) could help restore healthy lung tissue in people with IPF.
-
Neonatal Brain Injury Protection with New Purine Compounds
A new medication approach using purine derivatives is being studied to protect newborn brains from injury caused by limited blood flow and oxygen during birth.
-
Aldo-keto reductase (AKR) helps brain BH4 levels after injury
This grant tests whether brain AKR enzymes can boost BH4 levels and support better brain function after hypoxia-ischemia-related injury.
-
Dual-hypoxia and proliferation PET biomarker for recurrent glioblastoma
A study using a special PET imaging approach to map oxygen-poor areas and cell growth in recurrent brain tumors to guide treatment decisions.
-
How low oxygen and genetic tweaks may repair mitochondrial problems linked to Alzheimer’s and other disorders
A Johns Hopkins-style? (Note: institution specified later) patient-facing overview: researchers will study tiny cell power stations in mitochondria to see if low-oxygen conditions and specific genetic changes can fix problems associated with Alzheimer's disease and related dementias.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.